Table 3 Discontinuation rates due to adverse events in advanced hepatocellular carcinoma patients received ramucirumab
|  | All patient (n = 37) | P value |
|---|---|---|
Any | 4 (10.8%) | Â |
Age | Â | 0.34 |
  < 73 years (n = 18) | 3 (8.1%) |  |
  ≥ 73 years (n = 19) | 1 (2.7%) |  |
ECOG-PS | Â | 1 |
 0 (n = 24) | 0 (0%) |  |
  ≥ 1 (n = 13) | 4 (2.7%) |  |
Child–Pugh class |  | 0.016 |
 A (n = 30) | 3 (8.1%) |  |
 B (n = 7) | 1 (2.7%) |  |
BCLC stage | Â | 0.296 |
 A or B (n = 16) | 3 (8.1%) |  |
 C (n = 21) | 1 (2.7%) |  |